Search

Author/Creator Ahmadi, Tahamtan

1. 412 First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors. (10th December 2020)

Authors:
Garralda, Elena; Geva, Ravit; Ben-Ami, Eytan; Maurice-Dror, Corinne; Calvo, Emiliano; LoRusso, Patricia; Türeci, Özlem; Niewood, Michelle; Şahin, Uğur; Jure-Kunkel, Maria; Forssmann, Ulf; Ahmadi, Tahamtan; Melero, Ignacio
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A250
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation. (10th December 2020)

Authors:
Muik, Alexander; Altintas, Isil; Kosoff, Rachelle; Gieseke, Friederike; Schödel, Kristina; Salcedo, Theodora; Burm, Saskia; Toker, Aras; Kranz, Lena; Vormehr, Mathias; Eisel, David; Fereshteh, Mark; Türeci, Özlem; Breij, Esther; Ahmadi, Tahamtan; Sahin, Ugur; Jure-Kunkel, Maria
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A338
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation. (9th November 2020)

Authors:
Muik, Alexander; Altintas, Isil; Kosoff, Rachelle; Gieseke, Friederike; Schödel, Kristina; Salcedo, Theodora; Burm, Saskia; Toker, Aras; Kranz, Lena; Vormehr, Mathias; Eisel, David; Fereshteh, Mark; Türeci, Özlem; Breij, Esther; Ahmadi, Tahamtan; Sahin, Ugur; Jure-Kunkel, Maria
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A595
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation. (31st December 2022)

Authors:
Muik, Alexander; Altintas, Isil; Gieseke, Friederike; Schoedel, Kristina B; Burm, Saskia M; Toker, Aras; Salcedo, Theodora W.; Verzijl, Dennis; Eisel, David; Grunwitz, Christian; Kranz, Lena M; Vormehr, Mathias; Satijn, David P.E.; Diken, Mustafa; Kreiter, Sebastian; Sasser, Kate; Ahmadi, Tahamta...
Journal:
Oncoimmunology
Issue:
Volume 11:Number 1(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD. (2nd August 2016)

Authors:
Usmani, Saad; Ahmadi, Tahamtan; Ng, Yvette; Lam, Annette; Desai, Avinash; Potluri, Ravi; Mehra, Maneesha
Journal:
Oncologist
Issue:
Volume 21:Number 11(2016)
Page Start:
1355
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Analysis of Real‐World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD. (2nd August 2016)

Authors:
Usmani, Saad; Ahmadi, Tahamtan; Ng, Yvette; Lam, Annette; Desai, Avinash; Potluri, Ravi; Mehra, Maneesha
Journal:
Oncologist
Issue:
Volume 21:Number 11(2016)
Page Start:
1355
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Issue 10192 (6th July 2019)

Authors:
Moreau, Philippe; Attal, Michel; Hulin, Cyrille; Arnulf, Bertrand; Belhadj, Karim; Benboubker, Lotfi; Béné, Marie C; Broijl, Annemiek; Caillon, Hélène; Caillot, Denis; Corre, Jill; Delforge, Michel; Dejoie, Thomas; Doyen, Chantal; Facon, Thierry; Sonntag, Cécile; Fontan, Jean; Garderet, Laurent; ...
Journal:
Lancet
Issue:
Volume 394:Issue 10192(2019)
Page Start:
29
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Combined lenalidomide, low‐dose dexamethasone, and rituximab achieves durable responses in rituximab‐resistant indolent and mantle cell lymphomas. Issue 2 (7th October 2013)

Authors:
Ahmadi, Tahamtan; Chong, Elise A.; Gordon, Amanda; Aqui, Nicole A.; Nasta, Sunita D.; Svoboda, Jakub; Mato, Anthony R.; Schuster, Stephen J.
Journal:
Cancer
Issue:
Volume 120:Issue 2(2014)
Page Start:
222
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Combined lenalidomide, low‐dose dexamethasone, and rituximab achieves durable responses in rituximab‐resistant indolent and mantle cell lymphomas. Issue 2 (7th October 2013)

Authors:
Ahmadi, Tahamtan; Chong, Elise A.; Gordon, Amanda; Aqui, Nicole A.; Nasta, Sunita D.; Svoboda, Jakub; Mato, Anthony R.; Schuster, Stephen J.
Journal:
Cancer
Issue:
Volume 120:Issue 2(2014)
Page Start:
222
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Issue 6 (June 2020)

Authors:
Usmani, Saad Z; Nahi, Hareth; Plesner, Torben; Weiss, Brendan M; Bahlis, Nizar J; Belch, Andrew; Voorhees, Peter M; Laubach, Jacob P; van de Donk, Niels W C J; Ahmadi, Tahamtan; Uhlar, Clarissa M; Wang, Jianping; Feng, Huaibao; Qi, Ming; Richardson, Paul G; Lonial, Sagar
Journal:
Lancet
Issue:
Volume 7:Issue 6(2020)
Page Start:
e447
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗